

8997

AGR2 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 18	Source/Isotype: Rabbit	UniProt ID: #O95994	Entrez-Gene Id: 10551
Product Usage Information	e	Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		AGR2 Antibody recognizes endogenous levels of total AGR2 protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala29 of human AGR2 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		Anterior gradient homolog 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family of proteins and a homolog of the <i>Xenopus laevis</i> cement gland protein (1). In normal human tissues, AGR2 is expressed most abundantly in intestinal cells. Research studies have found AGR2 is overexpressed in a number of adenocarcinomas, including those derived from breast, pancreas, ovary, prostate and esophagus (2-4). <i>In vitro</i> and <i>in vivo</i> studies have shown that AGR2 positively regulates cell growth and division, while its overexpression can promote cell transformation (5,6). The latter functions of AGR2 were shown to involve YAP1-mediated up-regulation of amphiregulin expression, implicating AGR2 in both the EGF and Hippo kinase signaling pathways (6).				
Background References		1. Maresh, E.L. et al. (2010) <i>BMC Cancer</i> 10, 680. 2. Pizzi, M. et al. (2012) <i>Appl Immunohistochem Mol Morphol</i> 20, 31-6. 3. Wang, Z. et al. (2008) <i>Cancer Res</i> 68, 492-7. 4. Park, K. et al. (2011) <i>Exp Mol Med</i> 43, 91-100. 5. Vanderlaag, K.E. et al. (2010) <i>Breast Cancer Res</i> 12, R32. 6. Dong, A. et al. (2011) <i>J Biol Chem</i> 286, 18301-10.				
Background References		cell growth and division, while its overexpression can promote cell transformation (5,6). The latter functions of AGR2 were shown to involve YAP1-mediated up-regulation of amphiregulin expression implicating AGR2 in both the EGF and Hippo kinase signaling pathways (6). 1. Maresh, E.L. et al. (2010) <i>BMC Cancer</i> 10, 680. 2. Pizzi, M. et al. (2012) <i>Appl Immunohistochem Mol Morphol</i> 20, 31-6. 3. Wang, Z. et al. (2008) <i>Cancer Res</i> 68, 492-7. 4. Park, K. et al. (2011) <i>Exp Mol Med</i> 43, 91-100. 5. Vanderlaag, K.E. et al. (2010) <i>Breast Cancer Res</i> 12, R32.				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of their respective owners. We can be a constant of the property of t

more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for

diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.